Clinical Trial: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Leptomeningeal Disease
Study Type: INTERVENTIONAL
Official Title: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast
Brief Summary:
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease
Read more